Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05396456

Autologous Muscle Fiber Fragment Injections

To regenerate functional anal sphincter muscle using muscle fiber fragments that contain muscle precursor cells (MPCs)

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Wake Forest University Health Sciences

Winston-Salem, North Carolina, 27157, United States

Location status: Recruiting

Location contact

Mary-Clare Day, RN, BSN

CONTACT

[email protected]

336-713-1343

About this study

The Study hypothesizes that efficient re-assembly of injected fragments within host muscle tissue along the fiber direction of native muscle will be induced. It is anticipated that these fiber fragments would integrate into the host vascular and neural network.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 18 years of age
  • participants must experience 4 or more Fecal Incontinence (FI) episodes per 2 week period
  • participants must score >10 on Cleveland Clinic Fecal Incontinence Severity Scoring System (CCIS)
  • participants must have had symptoms for at least 12 months
  • participants who have failed standard medical and surgical treatments for FI
  • participant will undergo anorectal manometry (ARM) testing
  • participants will undergo endoscopic anal ultrasound and demonstrate an anatomic defect of the anal sphincter complex of at least 30 degrees
  • women of childbearing potential must use acceptable contraceptives during this study

Exclusion criteria

  • participants with symptomatic anorectal disease including symptomatic hemorrhoid disease, anal fissure or fistula causing symptoms such as bleeding, swelling, pain, or drainage
  • participants with pre-existing ano-rectal pain of any cause
  • participants with incontinence of flatus only
  • chronic watery diarrhea which is the primary cause for fecal incontinence
  • acute or chronic anorectal infections (including proctitis, recurrent abscesses, fistulae)
  • presence of anorectal tumors
  • active proctitis or inflammatory bowel disease
  • previous injection of internal anal sphincter (IAS) with bulking agents
  • participants requiring immunosuppression or who have any malignant disease within 3 years of enrollment
  • participants with a defined bleeding disorder diagnosed and treated by a hematologist
  • other exclusions include history of pelvic radiation, rectal prolapse, anorectal malformations, anorectal surgery within the previous 12 months, or treatments using injection or infrared coagulation for treatment of hemorrhoids
  • participants with neurologic disease characterized by significant peripheral neuropathy or spinal cord dysfunction
  • women who are pregnant, breastfeeding, or have had a child within the last year
  • participants with a history of unstable cardiac function (New York Heart Association Functional Classification III or IV) or unstable pulmonary function requiring home oxygen, or abnormal kidney function (Cr >1.5 mg/dl or on dialysis) or uncontrolled diabetes (Hemoglobin A1C > 8 mg/dl)
  • participants with anemia (hemoglobin <10g, increased alanine aminotransferase (ALT) and aspartate aminotransferase (AST) >2 times normal) or increased bilirubin >1.5mg/dl
  • participants with Hepatitis B or C, or human immunodeficiency virus (HIV)-1 or 2
  • rectal prolapse
  • vaginal prolapse beyond the hymen
  • unable to understand informed consent information even with provision of a medical translator

Treatment and study plan

Muscle Fiber Fragment (MFF) Injections

Procedure

The participant will be treated with an injection of muscle fiber fragments into the external anal sphincter at 3, 6, 9 and 12 o'clock using a 21-gauge needle to a depth of 1-2 cm from the external skin using equal amounts in each quadrant.

Primary outcomes

  1. Cleveland Clinic Fecal Incontinence Severity Scoring System (CCIS) scores (also termed the Wexner score)

    Time frame: Month 3

    fecal incontinence score from 0-20; where 0 is perfect continence and 20 is complete incontinence

  2. Cleveland Clinic Fecal Incontinence Severity Scoring System (CCIS) scores (also termed the Wexner score)

    Time frame: Month 6

    fecal incontinence score from 0-20; where 0 is perfect continence and 20 is complete incontinence

  3. Cleveland Clinic Fecal Incontinence Severity Scoring System (CCIS) scores (also termed the Wexner score)

    Time frame: Month 12

    fecal incontinence score from 0-20; where 0 is perfect continence and 20 is complete incontinence

Secondary outcomes

  1. Change in Fecal Incontinence Quality of Life (FI-QOL) scores

    Time frame: baseline, Months 3 and 12

    The Fecal Incontinence Quality of Life Scale is composed of a total of 29 items; these items form four scales: Lifestyle (10 items), Coping/Behavior (9 items), Depression/Self-Perception (7 items), and Embarrassment (3 items).

  2. Anorectal Manometry (ARM) Pressure scores

    Time frame: baseline, Months 3 and 12

    Low resting pressure is defined as <50 mmHg during the anorectal motility exam performed with high-resolution catheter (Given, Atlanta, GA). Normal resting pressures range from 50 to 100 mmHg.

    A flexible catheter with solid-state pressure transducers is placed in the anal canal and rectum to obtain standard pressure measurements

  3. Internal Anal sphincter (IAS) Pressure scores

    Time frame: baseline, Months 3 and 12

    Typical resting pressure in a healthy volunteer is 40 to 60 mmHg

  4. Rectal Anal Inhibitory Reflex (RAIR) Pressure scores

    Time frame: baseline, Months 3 and 12

    Low resting pressure is defined as <50 mmHg during the anorectal motility exam performed with high-resolution catheter (Given, Atlanta, GA). Normal resting pressures range from 50 to 100 mmHg.

    A flexible catheter with solid-state pressure transducers is placed in the anal canal and rectum to obtain Rectal Anal Inhibitory Reflex (RAIR)

  5. Fecal Incontinence Severity Index (FISI) scores

    Time frame: baseline, Months 3 and 12

    Participants who score closer to 61 are likely to have their quality of life severely impacted by the fecal incontinence they suffer from.

Other outcomes

  1. Anorectal endoscopic ultrasound (EUS)

    Time frame: Months 3 and 12

    This standard procedure is performed with a rotating rectal probe without sedation or deep sedation

Study contacts

Contact information is provided by the study sponsor or research team.

Mary-Clare Day, RN, BSN

CONTACT

[email protected]

336.713.1343

Sponsors and collaborators

Lead sponsor

Wake Forest University Health Sciences

Other

Registry information

Official study title

Autologous Muscle Fiber Fragment Injections for the Treatment of Fecal Incontinence

Important dates

Study start
2023
Primary completion
2029
Study completion
2029
First posted
May 31, 2022
Registry last updated
Feb 27, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.